Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

18F-DOPA PET/CT unravels malignant paraganglioma mimicking temporomandibular joint disorder.

Terzic A, Becker M, Wissmeyer M, Scolozzi P.

Dentomaxillofac Radiol. 2011 Jul;40(5):315-9. doi: 10.1259/dmfr/22707693.

2.

Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K.

J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28.

3.

Clinical utility of fluoride-18 positron emission tomography/CT in temporomandibular disorder with osteoarthritis: comparisons with 99mTc-MDP bone scan.

Lee JW, Lee SM, Kim SJ, Choi JW, Baek KW.

Dentomaxillofac Radiol. 2013;42(2):29292350. doi: 10.1259/dmfr/29292350.

4.

Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.

Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, Galli G, Fanti S, Giordano A.

Nucl Med Commun. 2011 Jul;32(7):575-82. doi: 10.1097/MNM.0b013e328345a340.

PMID:
21471850
5.

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8. doi: 10.1007/s00259-013-2548-y. Epub 2013 Sep 27.

PMID:
24072345
6.

The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.

Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P.

Endocr Relat Cancer. 2009 Mar;16(1):255-65. doi: 10.1677/ERC-08-0229. Epub 2008 Dec 16. Erratum in: Endocr Relat Cancer. 2009 Jun;16(2):661.

7.

6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP.

J Clin Endocrinol Metab. 2009 Oct;94(10):3922-30. doi: 10.1210/jc.2009-1054. Epub 2009 Jul 21.

PMID:
19622618
8.

Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K.

J Natl Cancer Inst. 2012 May 2;104(9):700-8. doi: 10.1093/jnci/djs188. Epub 2012 Apr 18.

9.

Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?

Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.

Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8.

PMID:
18330088
10.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
11.

The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.

Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT, Pacak K.

J Nucl Med. 2007 Oct;48(10):1599-606. Epub 2007 Sep 14.

12.

18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.

Marzola MC, Chondrogiannis S, Grassetto G, Rampin L, Maffione AM, Ferretti A, Opocher G, Schiavi F, Colletti PM, Rubello D.

Clin Nucl Med. 2014 Jan;39(1):e53-8. doi: 10.1097/RLU.0b013e31829aface.

PMID:
23856824
13.

The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W.

Eur Radiol. 2009 Jun;19(6):1425-34. doi: 10.1007/s00330-008-1280-7. Epub 2009 Jan 21.

PMID:
19156423
14.

Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.

Ambrosini V, Tomassetti P, Rubello D, Campana D, Nanni C, Castellucci P, Farsad M, Montini G, Al-Nahhas A, Franchi R, Fanti S.

Nucl Med Commun. 2007 Jun;28(6):473-7.

PMID:
17460538
15.

Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.

Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, Rufini V, Giordano A.

Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1144-53. doi: 10.1007/s00259-012-2087-y. Epub 2012 Feb 23. Review.

PMID:
22358431
16.

Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG.

J Clin Oncol. 2008 Mar 20;26(9):1489-95. doi: 10.1200/JCO.2007.15.1126.

17.

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL.

Lancet Oncol. 2006 Sep;7(9):728-34.

PMID:
16945767
18.

18F-DOPA positron emission tomography for the detection of glomus tumours.

Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, Neumann HP.

Eur J Nucl Med Mol Imaging. 2003 May;30(5):689-94. Epub 2003 Mar 5.

PMID:
12618904
19.

Role of (18) F-FDOPA PET/CT imaging in endocrinology.

Santhanam P, Taïeb D.

Clin Endocrinol (Oxf). 2014 Dec;81(6):789-98. doi: 10.1111/cen.12566. Epub 2014 Sep 1. Review.

PMID:
25056984
20.

(18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.

Magnaldi S, Mayerhoefer ME, Khameneh A, Schuetz M, Javor D, Mitterhauser M, Dudczak R, Hacker M, Karanikas G.

Anticancer Res. 2014 Feb;34(2):791-5.

PMID:
24511014
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk